Small RNA-based therapy for pulmonary arterial hypertension: miR-let-7f-1 inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 21/May/2015, 23.09

Small molecule-based Lifespan extension therapy: E6AP extends mammalian life span via up regulation of its target gene BubR1, 21/May/2015, 22.49
May 21, 2015
Natural product-based therapy for DM: Berberine lowers hepatic glucose production and plasma glucose levels via up regulation of its target gene, 21/May/2015, 23.17
May 21, 2015
Show all

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054] by Prof. Thistlethwaite PA, Li X and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small RNA-based therapy for pulmonary arterial hypertension: miR-let-7f-1 inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3

Significance:  miR-let-7f-1, by decreasing the expression of its target gene, it may suppress the expression of Notch3. Thus, pharmacological formulations encompassing miR-let-7f-1 activators” may be used to treat pulmonary arterial hypertension

Undisclosed information: How miR-let-7f-1 decreases the expression of Notch3 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Small RNA-based therapy for pulmonary arterial hypertension: miR-let-7f-1 inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 21/May/2015,  23.09,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.